Dr. Laurence J. Downey, President and CEO of Solvay Pharma Inc., discusses the economic value of new medications as well as the issues affecting the approval process and patient access in Canada. He compares the drug approval process in Canada to other countries and suggests ways for improving the system so that the needs of patients and clinicians in Canada are more effectively addressed.

Approx. 16 minutes
20 slides
Date: 2006/01
Location: Montreal, Quebec